ProCE Banner Activity

Prospective Molecular MRD Detection in AML by Next-Generation Sequencing

Slideset Download
Conference Coverage
This large prospective study shows that identification of residual leukemia by targeted next-generation sequencing of select mutations present in CR serves as a strong independent predictor for AML relapse and survival.

Released: December 14, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology